Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Nvo save search
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Published: 2024-03-25 (Crawled : 10:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.19%
H: 0.97%
C: 0.04%
disease pipeline pharmaceuticals acquire cardiovascular
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.09%
H: 1.41%
C: 0.94%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.01%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
ALPN | $64.58 0.05% 0.03% 1.6M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: -6.9%
bleeding disease market
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published: 2023-09-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
BSX | $68.02 1.03% 0.0% 7.7M
|
Health Technology
|
| O: -0.09%
H: 0.72%
C: -1.29%
SLN | $22.5 -0.62% -0.22% 170K
|
Health Technology
|
| O: -1.3%
H: 2.44%
C: -1.42%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
MESO | $5.53 6.14% 5.44% 270K
|
Health Technology
|
| O: 3.25%
H: 1.57%
C: -3.15%
IONS | $41.07 0.96% 0.97% 710K
|
Health Technology
|
| O: 0.99%
H: 2.09%
C: 0.83%
AMGN | News | $271.91 1.11% 1.12% 1.4M
|
Health Technology
|
| O: 1.0%
H: 0.69%
C: -1.01%
disease cardiovascular growth market
Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast 2023-2032: With Focus on United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Published: 2023-06-28 (Crawled : 02:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: -0.94%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: -2.09%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.1%
H: 5.34%
C: 0.82%
disease japan kidney market
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.78 0.42% 0.63% 140K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $15.99 -0.06% -0.06% 3.1M
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | $0.4832 -0.68% -0.58% 440K
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $194.11 -0.14% -0.15% 930K
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $3.68 -2.65% -2.72% 1.4M
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Published: 2022-09-01 (Crawled : 12:20) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -1.0%
H: 0.41%
C: -0.49%
MC | $53.22 3.04% 0.0% 690K
|
Finance
|
| O: -0.62%
H: 0.82%
C: 0.63%
FMTX | $20.01 -0.15%
|
Health Technology
|
| O: 48.87%
H: 2.27%
C: 2.07%
blood rare acquire disease therapeutics
Global Acquired von Willebrand Disease (AvWD) Treatment Market Report 2022-2030 Featuring Key Players - Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA
Published: 2022-07-25 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 630
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.83%
H: 0.67%
C: 0.32%
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
|
| O: 0.76%
H: 0.19%
C: -1.06%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 2.0%
H: 0.0%
C: 0.0%
treatment global disease report roche acquired sanofi market
Valued to be $12.9 Billion by 2026, Crohn`s Disease (CD) Therapy Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 12:20) - prnewswire.com
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.78%
H: 0.94%
C: 0.26%
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -4.88%
H: 1.04%
C: -1.25%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
disease therapy growth
Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases
Published: 2022-05-11 (Crawled : 12:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -2.55%
H: 2.32%
C: -0.85%
therapeutics disease
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Global Oral Biologics & Biosimilar Drugs Markets 2021-2030: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis
Published: 2021-08-06 (Crawled : 15:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -4.5%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% 0.57% 3.5M
|
Health Technology
|
| O: -0.95%
H: 0.23%
C: -0.3%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
ENTX | $2.05 3.02% 5.24% 170K
|
Health Technology
|
| O: 2.23%
H: 0.0%
C: -1.39%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: -2.02%
H: 0.09%
C: -1.38%
RVP P | $1.07 0.94% 0.0% 22K
|
Health Technology
|
| O: -0.08%
H: 1.82%
C: 0.87%
multiple sclerosis disease diabetes drug sclerosis psoriasis biosimilar
Biologics Market Size to Reach USD 477.15 Billion in 2027 | Rapid Advancements in Molecular Therapy and Cell-Based Biologics, Increasing Incidence of Chronic Diseases, are Some Key Factors Driving Industry Growth, says Emergen Research
Published: 2021-07-29 (Crawled : 15:15) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.33%
H: 0.35%
C: -0.32%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: 0.4%
H: 0.08%
C: -0.13%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.69%
H: 0.08%
C: -0.33%
disease therapy molecular growth research merge
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
Published: 2021-07-09 (Crawled : 04:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
disease neurodegenerative
Novo Holdings Launches Muna Therapeutics with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
Published: 2021-07-09 (Crawled : 04:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
disease neurodegenerative
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.